No mention of PBT2 in quarterly report. Obviously a very low priority for ATH. Also difficult to comprehend why Australia was not one of the first countries to commence the ATH434 phase 2 studies. Not sure if TGA slow in approving the phase 2 trial or just that ATH was not targeting Australia to initiate trials.
Also seems a strange fit with the amyloidosis treatment patent which is not considered a neurodegenerative disease.
Anyway what is sure that ATH is in no hurry on any front. Will also be interesting to see how they deal with the possible delisting of ATHE if share price does not revisit $1.00 in the next month or so. Could be a reverse share split or they could surprise us all and announce a break through on antibiotic resistance by the use of PBT2 with Zinc.
GLTAH
Ann: Appendix 4C and Quarterly Cash Flow Report, page-2
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(11.1%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $14.25K | 2.930M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 66 | 81346070 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 19609447 | 23 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |